Background. Chronic hepatitis C virus (HCV) infection is a global health problem, resulting in liver failure, hepatocellular carcinoma, and liver-related death. Natural killer (NK) cells are innate immune cells, and their activity is known to correlate to viral treatment response of HCV. In this study, we investigate the immune effects of viral load decline with direct-acting antivirals (DAAs) in blood.
Chronic hepatitis C virus (HCV) infection is a disease that affects about 170 million people worldwide. Chronic infection of HCV can lead to mortality from hepatic as well as extra-hepatic causes [1] . Until recently, the standard-of-care therapy of chronic HCV patients was based on the use of pegylatedinterferon (IFN)-α and ribavirin. The recent development of highly potent, IFN-free direct-acting antiviral (DAA) compounds that specifically inhibit NS3 protease activity or NS5 polymerase activity has demonstrated superior antiviral activity compared to IFN-based therapy and has less adverse events [2] . In a phase III clinical trial, combined treatment with the NS3B protease inhibitor asunaprevir and the NS5A polymerase inhibitor daclatasvir resulted in sustained viral response (SVR) rates of 80%-85% in chronic HCV patients with genotype 1 [3] .
In blood as well as the liver of chronic HCV patients, the HCV-specific immune responses are weak or absent because of the continuous antigenic pressure resulting from high concentrations of viral antigens [4] . Viral load decline as a consequence of therapy of chronic HCV patients offers a unique opportunity to determine whether the reported impaired immunity to HCV can be restored. However, this could not be previously investigated during IFN-based therapy, because pegylated-IFN-α directly modulates immune parameters. The IFN-induced effects include: leukopenia, inhibition of CD4 + and CD8 + T-cell proliferation, direct activation of natural killer (NK) cells, and suppression of interleukin (IL)-12 production by monocytes. These are considered direct immunomodulatory effects of pegylated-IFN-α, and not related to viral load decline. Recently, 2 studies have examined immune effects during treatment of chronic HCV patients with DAA in the absence of pegylated-IFN-α. These studies observed a rapid downregulation of IFN-stimulated gene (ISG) expression in the liver and blood [5] , and enhanced HCV-specific CD8 + T-cell responses in blood of successfully treated patients [6] . Besides T cells, natural killer (NK) cells are also important mediators of the antiviral immune response to HCV. Although conflicting data have been reported in HCV regarding the quality of the NK cell response during the chronic HCV infection [7] [8] [9] , their roles during IFN-based therapy as a predictor of treatment efficacy has been well documented [10, 11] , and are likely related to the direct effect of IFN-α on NK cells [12] . NK cell activity is controlled by various inhibitory receptors such as NKG2A and killer immunoglobulin-like receptors (KIRs), which sense downregulation of major histocompatibility complex class I molecules on virus-infected cells. Other receptors such as NKG2C/D and NKp30, and NKp44 and NKp46 deliver activation signals and shift the balance to an activated state of NK cells during chronic HCV infection [13, 14] . Importantly, variations in haplotype of KIRs and human leukocyte antigens (HLAs) have been associated with spontaneous and treatment-induced HCV clearance, indicating an important role for NK cells in viral elimination [15, 16] .
In the present study, we evaluate the functionality of circulating NK cells in chronic HCV patients during viral decline induced by IFN-free DAA therapy using asunaprevir and daclatasvir. This information is important for a better understanding of the effect of HCV virus eradication on the immune response and to determine the factors that influence protection against reinfection.
MATERIAL AND METHODS

Patients and Healthy Subjects
Twelve chronic HCV patients, genotype 1b, received daclatasvir (60 mg, orally, once daily) and asunaprevir (100 mg, orally, twice daily) for 24 weeks. The study was an investigator-initiated single-center study at the department of Gastroenterology and Hepatology of the Erasmus Medical Center (MC), the Netherlands. Patients were previous nonresponders to peginterferon and ribavirin therapy and had no signs of coinfection with HBV and/or HIV. Patients with evidence of hepatocellular carcinoma or cirrhosis Child-Pugh grade B or C were excluded. Patients' blood samples were obtained at screening, baseline, 3 days, and 1, 2, 4, 8, and 12 weeks after start of therapy. HCV RNA was determined with COBAS Taqman assay. Blood samples from 12 age-and sex-matched healthy subjects were used as controls for this study. The institutional ethical review board of the Erasmus MC approved the protocols, and informed consent was obtained from all individuals.
Analysis of Cell Surface Molecule Expression by Flow Cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood by ficoll separation (Ficoll-Paque Plus, Amersham). For NK cell phenotype, cells were stained for 20 minutes with CD56-APC-eFluor780 (CMSSB), CD16-PerCp-eFluor710 (eBioCB16), HLA-DR-PerCp-Cy5.5 (LN3), CD69-PE-Cy7 (TP1.55.3), CD3-FITC (UCHT1), and StreptavidineFluor450 (all eBioscience), NKp46-APC (185 314), NKG2A-PE (Z199), NKp30-PE (Z25, all Beckman), CD3-PacificBlue (UCHT1), NKG2D-PerCp-Cy5.5 (ID11, all BD Bioscience), NKp44-Biotin (P44-8, Biolegend), NKG2C-Alexa-488 (134 591, R&D), and Aqua life/dead marker (Life Technologies). In addition, for granzyme B, perforin and tumor necrosis factor (TNF)-related apoptosis-induced ligand (TRAIL) staining, frozen PBMCs were thawed, fixed with 2% formaldehyde, permeabilized with 0.5% saponin, and stained with perforinPerCp-Cy5.5, granzyme B-PE (GB-11), CD56-APC-eFluor780 (CMSSB), CD8-APC (SK1), CD69-PE-Cy7 (FN50, all eBioscience), CD3-PB (UCHT), CD4-PE-Cy7 (SK3, both BD Bioscience), TRAIL-AlexaFluor488 (75 402 
Assessment of the Cytokine Levels Using Multiplex Immunoassays
Serum samples were collected and cytokine levels were determined using Procarta Plex human cytokine/chemokines multiplex immunoassays (eBioscience, Vienna, Austria). The concentrations of 39 distinct analytes were determined, measured using the microsphere-based multiplex LUMINEX-100 (Supplementary Table 1 ).
Gene Expression Analysis
For gene expression analysis using microarray, blood was collected in Tempus RNA tubes at weeks 0, 1, 2, 4, 8, and 12. RNA was isolated from whole blood. Gene expression was evaluated using GeneChip Human Genome U133 Plus 2.0 arrays (Affymetrix). Sample preparation, microarray, and processing of array data are described elsewhere [17] . For each gene, the expression at baseline was compared to its expression during therapy using significant analysis of microarray for 2 classpaired samples. To correct multiple testing, false discovery rate (FDR) approach was controlled by randomly permutating the class of samples 1000 times. The differentially expressed genes were identified by a change factor ≥2. Different cut-offs of FDR-adjusted P value (q value) were used for different SAM (significance analysis of microarrays) comparisons to get a comparable number of differentially expressed genes. All analysis was performed in R statistical software.
Statistics
Statistical comparison used for microarray analyses is described above. 
RESULTS
Recovery of HCV-specific T Cells and Downregulation of ISGs During IFN-free Therapy
Combination therapy with asunaprevir and daclatasvir has shown to be an effective treatment for chronic HCV [3] . Twelve patients were treated in a clinical trial, which was designed to evaluate in detail the functionality of immune cells in blood in chronic HCV patients before, during, and after treatment with asunaprevir and daclatasvir, in an IFN-free regimen. Patient characteristics are shown in Table 1 . Eleven out of 12 patient in our treatment cohort obtained an initial treatment response, defined as undetectable HCV RNA (<15 U/mL) at week 8. One patient developed a viral breakthrough at week 4 during therapy and stopped treatment immediately. HCV RNA and alanine transaminase levels during therapy are depicted in Figure 1A .
We first examined the effect of IFN-free therapy on the frequency of HCV-specific CD8 + T cells at various time points in Microarray analyses on whole blood demonstrated that predominantly ISGs were significantly upregulated in chronic HCV patients compared to healthy controls (Supplementary Table 2 ). Gene expression levels were compared at weeks 1, 2, 4, 8, and 12 during therapy with baseline. Genes with a more than 2-fold modulation in expression are presented in Table 2 . During treatment, a downregulation of ISGs was observed, including members involved in antiviral activity (RSAD2, OAS3, IFIT1, and ISG15) and ligands for chemokine receptor CXCR3 (CXCL10 = IP-10) ( Figure 2 and Table 2 (Figure 3 ). We observed that chronic HCV patients show higher NK bright and lower NK dim frequencies compared to healthy controls (P = .02, P = .02, respectively). Interestingly, during the first 12 weeks of IFN-free therapy, NK cell frequencies altered to levels comparable to healthy controls (Figure 3) , suggesting a direct effect of viral load decline on the composition of the NK cell compartment.
DAA Therapy Downregulates Surface NKp30, NKp46, and NKG2A Expression on NK Cells to a Phenotype Resembling Healthy Controls
To investigate whether the decrease in activation was reflected by their NK cell phenotype, we determined activation and inhibitory receptors on the surface of NK cells. Our results showed that the activation receptor NKp30 was downregulated on total NK cells. Because the decrease in expression was linear, we could determine a slope (β) and corresponding P value ( Figure 4) . Expression of the activation receptor NKp46 was also decreasing upon IFN-free therapy, suggesting a lower activation state (P < .0001, Figure 4 and Supplementary Figure 3) . Another important group of surface molecules are C-type lectins, which include inhibitory as well as activating receptors. Expression of the activating receptors CD69, CD16, NKG2C, and NKG2D on NK cells was not affected by therapy (Supplementary Figure 4 ). However, there was a clear decrease of the frequency of the inhibitory receptor NKG2A on total NK and NK dim cells (P = .001 and P = .012, respectively) ( Figure 4 and Supplementary Figure 3) . Importantly, no differences, except for the expression of NKp46 on NK bright and NK dim cells, were observed for NK cell markers comparing the expression between HCV patients at week 12 and healthy controls. This suggests that the NK cell phenotype is already normalized at week 12. For each gene, the expression at baseline was compared to its expression at various time points during therapy. The differentially expressed genes were identified with a fold change of ≥ 2.
Abbreviations: HCV, hepatitis C virus; IFN, interferon.
Viral Load Reduction Decreases NK Cell-Related Cytokines in Serum and TRAIL Expression
Because we observed an effect of IFN-free therapy on NK cell frequencies and NK surface molecules, we next determined if certain NK cell functions were modulated. IFN-γ production by NK cells was determined upon IL-12/IL-18 stimulation but showed no difference among all time points during therapy (Supplementary Figure 5A) . In addition, IFN-free therapy did not alter the frequencies of total NK cells, or NK dim and NK bright cells producing perforin or granzyme B (Supplementary Figure 5B , and data not shown) or specific killing of K562 target cells or suppression of viral replication by NK cells (Supplementary Figure 5C ). As shown in Figure 2 and Supplementary Figure 2 , we demonstrated significant downregulation of ISG mRNA expression, as well as reduced serum levels of eotaxin, MIP-1β, and IP-10, which act as chemoattractants. Other cytokines, including IL-12 and IL-18, promote NK cell activation [18] . Comparison of serum levels of these cytokines at baseline showed that IL-12p40 and IL-18 levels were lower in healthy individuals compared to chronic HCV patients (P < .001, P = .002, respectively). Importantly, both serum IL-12p40 and IL-18 levels decreased significantly during treatment-induced viral load decline; however, this was not sustained at week 12 ( Figure 5A ). Of interest, serum-soluble TRAIL levels were lower in healthy controls compared to HCV patients (P = .04) and showed a modest reduction during DAA therapy; however, this was not significant. Because TRAIL is expressed on the surface of NK cells and important for killing of hepatocytes, we determined TRAIL expression on NK cells by flow cytometry, and observed reduced frequencies of TRAIL expressing NK cells during therapy ( Figure 5B ). This decline of membrane-bound TRAIL (mTRAIL) expression was only observed for NK dim cells (data not shown). Combined, therapy-induced reduction of serum cytokines levels important for NK cell activation are indicative of a less activated state of NK cells, as shown by a decrease in the expression of activating receptors as well as TRAIL. 
DISCUSSION
Our study evaluated the immune effects during therapyinduced viral load decline in chronic HCV patients treated with daclatasvir and asunaprevir. We show that reduced HCV RNA load causes correction of the altered NK cell phenotype, including TRAIL, NKp30, and NKp46, whose expression diminished during DAA therapy to levels observed in healthy individuals. Furthermore, we confirmed a recent study by showing that viral load decline following successful DAA therapy led to reduction of blood ISG mRNA and restoration of the HCVspecific CD8 + T-cell compartment [6] .
Because NK cells directly respond to IFN-α in vitro [14, 19] , previous studies conducted in HCV patients during treatment with pegylated-IFN-α and ribavirin combination therapy demonstrated higher levels of activation markers compared to baseline [2, 8, 20] . Also, an increase in TRAIL expression on the surface was observed [21] . However, due to the direct effect of IFN-α on NK cells, the consequences of viral load decline on NK cells could not be examined, as we did in our study. In contrast to IFN-α therapy, DAA therapy led to a lowering of the activation state of blood NK cells, as reflected by reduced levels of TRAIL, NKp30, and NKp46 on NK cells and reduced serum levels of IL-12 and IL-18, likely due to the removal of the viral stimulus. Importantly, comparison of TRAIL expression on NK cells obtained from healthy individuals and HCV patients showed higher frequencies of TRAIL-expressing NK cells in patients prior to therapy (15.7% vs 3.8%; P < .0001). The simultaneous DAA-induced reduction of NKG2A levels on NK cells was unexpected, but might be the consequence of compensatory mechanisms exerted upon declining activating signals.
We performed a subanalysis for the 4 cirrhotic patients and did not observe that any of the parameters were differentially modulated during DAA therapy in cirrhotics as compared to noncirrhotics (data not shown). The subanalysis was conducted at baseline for serum IP-10, IL-18, IL-12p40, IL-12/IL-18-induced IFN-γ, perforin, granzyme B, and mTRAIL expression as well as the modulation during the course of therapy.
In line with the reversal of the activation state of blood NK cells, we observed a rapid downregulation of ISG mRNA, including RSAD2, OAS3, ISG15, and IFIT1 during DAA therapy. Because many ISG mRNAs are expressed at higher levels in the blood and liver during chronic infection [22, 23] , lowering the endogenous IFN system to a less active state by DAA therapy might enhance the responsiveness to IFN-based treatment, and be important for sustained eradication of the virus.
In our study, 11 patients were successfully treated with DAA and had undetectable serum HCV RNA at week 24. However, 1 patient experienced a viral breakthrough at week 4 during DAA therapy. Careful examination of the study parameters of this patient demonstrated no differences in gene expression levels, HCV-specific T-cell frequency, or serum cytokine levels compared with responder patients. The NK cell phenotype resembled that of the other patients, except for a lower expression of CD57 on NK dim cells during all time points of DAA therapy (28.7% vs 44.6% at baseline). While IFN-free therapy did not affect NKG2D or CD16 expression on NK dim cells, the patient with viral breakthrough showed an increased frequency of NKG2D-expressing NK cells and a decrease of CD16-expressing NK cells during therapy (Supplementary Figure 6) . Our present study provides a better understanding on the immune consequences of HCV eradication by IFN-free therapy.
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